EGM
GLUE icon

Engineers Gate Manager’s Monte Rosa Therapeutics GLUE Stock Holding History

Engineers Gate Manager’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,871
Closed -$80.6K – 2261
2025
Q3 		$80.6K Buy
+10,871
New +$57.6K ﹤0.01% 2027

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Engineers Gate Manager's GLUE Position: Q4 2025 in Review

Engineers Gate Manager sold out of Monte Rosa Therapeutics (GLUE) in Q4 2025, closing a stake of 10,871 shares — an estimated $80.6K sold.

Engineers Gate Manager first reported a position in GLUE in Q3 2025 and held it in 1 quarter. The position peaked at $80.6K in Q3 2025. 161 funds tracked by Wall St. Rank hold GLUE as of Q4 2025.

  • Engineers Gate Manager reported no remaining Monte Rosa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 10,871 Monte Rosa Therapeutics shares in Q4 2025, an estimated $80.6K.
  • Engineers Gate Manager first reported a position in Monte Rosa Therapeutics in Q3 2025 and held it in 1 quarter.
  • Engineers Gate Manager's Monte Rosa Therapeutics position peaked at $80.6K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2025.

Based on Engineers Gate Manager's 13F filing for Q4 2025, filed 17 Feb 2026.